Get the Stockscreener App
39.77
0.05%
0.02
After Hours:
39.77
Crinetics Pharmaceuticals Inc stock is traded at $39.77, with a volume of 739.80K.
It is up +0.05% in the last 24 hours and up +6.08% over the past month.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
See More
Previous Close:
$39.75
Open:
$39.63
24h Volume:
739.80K
Relative Volume:
0.68
Market Cap:
$4.16B
Revenue:
$7.70M
Net Income/Loss:
$-465.32M
P/E Ratio:
-8.0431
EPS:
-4.9446
Net Cash Flow:
$-383.68M
1W Performance:
-0.48%
1M Performance:
+6.08%
6M Performance:
-9.92%
1Y Performance:
+34.09%
1-Day Range:
$38.99
$40.03
1-Week Range:
$38.25
$40.44
52-Week Range:
$25.83
$57.99
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Name
Crinetics Pharmaceuticals Inc
Sector
Industry
Phone
858-450-6464
Address
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
39.77 | 4.16B | 7.70M | -465.32M | -383.68M | -4.9446 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-26 | Upgrade | Goldman | Neutral → Buy |
| Jul-10-25 | Initiated | Goldman | Neutral |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-11-25 | Initiated | TD Cowen | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Peer Perform |
| Jan-22-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Jan-16-24 | Initiated | Morgan Stanley | Overweight |
| Dec-21-23 | Initiated | Jefferies | Hold |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-31-23 | Initiated | Oppenheimer | Outperform |
| Apr-24-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Robert W. Baird | Outperform |
| Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
| Nov-23-21 | Initiated | Evercore ISI | Outperform |
| Jun-18-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-23-19 | Initiated | ROTH Capital | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Aug-13-18 | Initiated | JP Morgan | Neutral |
| Aug-13-18 | Initiated | Leerink Partners | Outperform |
| Aug-13-18 | Initiated | Piper Jaffray | Overweight |
View All
Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News
Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer - GlobeNewswire Inc.
CRNX (NASDAQ: CRNX) files Rule 144: 20,900-share exercise, prior 10b5-1 sales - Stock Titan
Insider Sales: CRNX (NASDAQ: CRNX) 4,434-share option sale; Knight 95,074 prior shares - Stock Titan
(CRNX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Fed Meeting: Is Crinetics Pharmaceuticals Inc stock a top performer YTD2026 Rallies & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B - MSN
Crinetics Pharmaceuticals Signs Independent Consultant Agreement with Jeff Knight – 8-K Filing Details and XBRL Information - Minichart
Crinetics Pharma chief dev officer sells $3.4m in stock By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals Insider Sold Shares Worth $3,415,036, According to a Recent SEC Filing - marketscreener.com
Crinetics (CRNX) COO exercises options and sells 85,163 shares under 10b5-1 - Stock Titan
Jeff Knight exits Crinetics (NASDAQ: CRNX) officer role, stays on under paid consulting deal - Stock Titan
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 - Sahm
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Brazil ANVISA Filing For PALSONIFY - Sahm
Crinetics Pharmaceuticals to Report Q1 2026 Results on May 7 - National Today
Aug Retail: Whats the beta of Crinetics Pharmaceuticals Inc stock2026 Major Catalysts & Precise Buy Zone Identification - baoquankhu1.vn
Insider sale: CRNX (NASDAQ: CRNX) files Form 144 for 9,911 shares on 03/16/2026 - Stock Titan
Crinetics sets May 7 earnings call, business update after close - Stock Titan
Aug Shorts: Is Crinetics Pharmaceuticals Inc a stock for growth or value investors2026 Recap & Trade Opportunity Analysis Reports - baoquankhu1.vn
Future of Pituitary Cancer Market (2026-2033) | Precision - openPR.com
Risk Hedge: Is Crinetics Pharmaceuticals Inc exposed to currency risks2026 Market WrapUp & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Why Crinetics Pharmaceuticals (CRNX) Is Up 10.6% After Brazil PALSONIFY Filing Expands Global Footprint - Sahm
Aberdeen Group plc Buys 334,584 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Price performance - Yahoo Finance Australia
Crinetics Pharmaceuticals Inc (6Z4.DU) stock price, news, quote and history - Yahoo Finance UK
Price-Driven Insight from (CRNX) for Rule-Based Strategy - Stock Traders Daily
CRNX Stock Price, Quote & Chart | CRINETICS PHARMACEUTICALS IN (NASDAQ:CRNX) - ChartMill
Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More - AOL.com
Crinetics Pharmaceuticals Director Sells Shares - intellectia.ai
Crinetics Pharmaceuticals Inc. (CRNX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
CRNX PE Ratio & Valuation, Is CRNX Overvalued - Intellectia AI
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Crinetics Pharma Director Stock SaleMarch 2026 Transaction DetailsNews and Statistics - IndexBox
Crinetics Pharma COO to step down - MSN
Crinetics Pharmaceuticals (NASDAQ:CRNX) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Crinetics submits application for acromegaly drug in Brazil By Investing.com - Investing.com Australia
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify (Paltusotine) in Acromegaly - Bitget
Vanguard disaggregates holdings; Crinetics (CRNX) parent reports 0 shares - Stock Titan
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly - The Manila Times
Crinetics submits application for acromegaly drug in Brazil - Investing.com
Crinetics Pharmaceuticals Announces Submission of Marketing - globenewswire.com
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B (XLV:NYSEARCA) - Seeking Alpha
Crinetics Pharmaceuticals (CRNX) Executive Resignation Announced - GuruFocus
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 4.3%Here's Why - MarketBeat
Crinetics Pharmaceuticals, Inc. Announces Resignation of Jeff Knight as Chief Development and Operating Officer, Effective on or About April 10, 2026 - MarketScreener
Crinetics Pharmaceuticals, Inc. Files Form 8-K with SEC: Company Details, Stock Info, and Compliance Data (March 2026) - Minichart
Crinetics Pharmaceuticals chief development and operating officer to resign By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals Inc Stock (CRNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):